{"id":164151,"date":"2024-08-29T07:34:53","date_gmt":"2024-08-29T11:34:53","guid":{"rendered":"https:\/\/44.250.171.167\/?p=164151"},"modified":"2024-08-29T07:34:54","modified_gmt":"2024-08-29T11:34:54","slug":"wanbury-faces-revenue-decline-in-q1fy25-amid-operational-challenges-sets-stage-for-recovery","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/wanbury-faces-revenue-decline-in-q1fy25-amid-operational-challenges-sets-stage-for-recovery\/","title":{"rendered":"Wanbury Faces Revenue Decline in Q1FY25 Amid Operational Challenges, Sets Stage for Recovery"},"content":{"rendered":"\n<p class=\"has-medium-font-size\"><strong>Company Overview:<\/strong> <\/p>\n\n\n\n<p>Wanbury Ltd., established in 1988, is a prominent player in the pharmaceutical industry. The company has a strong presence in the global API market and domestic branded formulations, exporting its products to over 50 countries. Wanbury\u2019s manufacturing facilities, located in Patalganga (Maharashtra) and Tanuku (Andhra Pradesh), are approved by USFDA and EUGMP. The company\u2019s diverse product portfolio includes APIs like Metformin, Sertraline, Tramadol, and Paroxetine, among others. Wanbury also has a significant presence in various therapeutic categories such as cough and cold solutions, gastro-intestinal treatments, and anti-inflammatory and analgesics.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Financial Performance Overview:<\/strong> <\/p>\n\n\n\n<p>Wanbury\u2019s financial performance for Q1FY25 reflects the challenges the company faced during the quarter. The company reported revenues of \u20b9131.11 Crores, a 10.38% decline compared to \u20b9146.29 Crores in Q1FY24. This significant decrease in revenue can be attributed to operational inefficiencies, particularly at the Patalganga manufacturing facility, which was undergoing upgradation and renovation during the quarter. The facility&#8217;s underutilization impacted production levels, leading to reduced sales.<\/p>\n\n\n\n<p>In terms of expenses, Wanbury managed to reduce its total expenses to \u20b9131.01 Crores in Q1FY25 from \u20b9141.91 Crores in Q1FY24, marking a 7.68% decrease. While this reduction in costs partially mitigated the impact of the lower revenue, it was not sufficient to prevent a sharp decline in profitability. The company&#8217;s EBITDA for the quarter stood at \u20b911.9 Crores, with an EBITDA margin of 9.1%, slightly lower than the 9.5% margin recorded in the previous year. The decline in operational efficiency, combined with lower revenue, resulted in a significant drop in profit after tax (PAT) to \u20b91.04 Crores, a 77.83% decrease from \u20b94.69 Crores in Q1FY24. Consequently, the PAT margin also contracted to 0.8% from 3.2% in the same period last year.<\/p>\n\n\n\n<p>Despite these financial challenges, Wanbury achieved a major operational milestone by successfully clearing the USFDA inspection at its Patalganga facility for the sixth time, with zero-483 observations. This accomplishment underscores the company\u2019s ongoing commitment to quality and regulatory compliance, even during a period of operational difficulties. Additionally, the company made strategic leadership changes, appointing Mr. V. Prakash as the Head of API business, a move aimed at driving future growth and enhancing the company\u2019s strategic direction.<\/p>\n\n\n\n<p>Looking ahead, Wanbury is expected to recover as it resumes full-scale operations at its key facilities and implements its strategic initiatives. The company\u2019s focus on cost reduction, efficiency improvements, and leadership changes positions it to enhance profitability in the subsequent quarters.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company Overview: Wanbury Ltd., established in 1988, is a prominent player in the pharmaceutical industry. The company has a strong presence in the global API market and domestic branded formulations, exporting its products to over 50 countries. Wanbury\u2019s manufacturing facilities, located in Patalganga (Maharashtra) and Tanuku (Andhra Pradesh), are approved by USFDA and EUGMP. The [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":134522,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392],"tags":[10162],"class_list":["post-164151","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":164014,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q1fy25-97-rise-in-profits\/","url_meta":{"origin":164151,"position":0},"title":"Glenmark Pharmaceuticals Ltd Q1FY25; 97% rise in Profits","author":"Divyansh_Kasana","date":"August 22, 2024","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q1FY25 of \u20b93,244.00 Crores up from \u20b93,036.00 Crore year on year, a rise of 6.85%. Total Expenses for Q1FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-150.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-150.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-150.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-150.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-150.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-150.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163825,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-ltd-q1fy25-26-fall-in-profits\/","url_meta":{"origin":164151,"position":1},"title":"Gland Pharma Ltd Q1FY25; 26% fall in Profits","author":"Divyansh_Kasana","date":"August 14, 2024","format":false,"excerpt":"Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":164086,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-ltd-q1fy25-91-rise-in-profits\/","url_meta":{"origin":164151,"position":2},"title":"Alkem Laboratories Ltd Q1FY25; 91% rise in Profits","author":"Divyansh_Kasana","date":"August 26, 2024","format":false,"excerpt":"Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. Financial Results: Alkem Laboratories Ltd reported Revenues for Q1FY25 of \u20b93,032.00 Crores up from \u20b92,968.00 Crore year on year, a rise of 2.16%. Total Expenses\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-172.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-172.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-172.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-172.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-172.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-172.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":164145,"url":"https:\/\/alphastreet.com\/india\/wanbury-ltd-q1fy25-78-fall-in-profits\/","url_meta":{"origin":164151,"position":3},"title":"Wanbury Ltd Q1FY25; 78% fall in Profits","author":"Divyansh_Kasana","date":"August 29, 2024","format":false,"excerpt":"Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research Financial Results: Wanbury Ltd reported Revenues for Q1FY25 of \u20b9131.11 Crores down from \u20b9146.29 Crore year on year, a fall of 10.38%. Total Expenses for Q1FY25 of \u20b9131.01 Crores down from \u20b9141.91 Crores year\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-189.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-189.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-189.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-189.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-189.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-189.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163926,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q1fy25-61-rise-in-profits\/","url_meta":{"origin":164151,"position":4},"title":"Aurobindo Pharma Ltd Q1FY25; 61% rise in Profits","author":"Divyansh_Kasana","date":"August 19, 2024","format":false,"excerpt":"Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. Financial Results: Aurobindo Pharma Ltd reported Revenues for Q1FY25 of \u20b97,567.00 Crores up from \u20b96,851.00 Crore year on year, a rise of 10.45%. Total Expenses for Q1FY25 of \u20b96,464.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":164766,"url":"https:\/\/alphastreet.com\/india\/hikal-ltd-q1fy25-26-fall-in-profits\/","url_meta":{"origin":164151,"position":5},"title":"Hikal Ltd Q1FY25; 26% fall in Profits","author":"Divyansh_Kasana","date":"October 9, 2024","format":false,"excerpt":"Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-50.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-50.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-50.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-50.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-50.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-50.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/164151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=164151"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/164151\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/134522"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=164151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=164151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=164151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}